Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 3/20 | 0.71 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | PDE4A | P27815 | 1/20 | 0.47 |
| ▸ | SNCA | P37840 | 1/20 | 0.47 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.41 |
| ▸ | CDC25B | P30305 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8079392 | 1.00 | PTPN1 (0.71) | PTPN1PTGS1PDE4ASNCAPDE3A | |
| SCHEMBL8079393 | 1.00 | PTPN1 (0.71) | PTPN1PTGS1PDE4ASNCAPDE3A | |
| SCHEMBL31133413 | 1.00 | PTPN1 (0.71) | PTPN1PTGS1PDE4ASNCAPDE3A | |
| SCHEMBL8082396 | 1.00 | PTPN1 (0.71) | PTPN1PTGS1PDE4ASNCAPDE3A | |
| SCHEMBL8082399 | 1.00 | PTPN1 (0.71) | PTPN1PTGS1PDE4ASNCAPDE3A | |
| SCHEMBL8079263 | 1.00 | PTPN1 (0.71) | PTPN1PTGS1PDE4ASNCAPDE3A | |
| SCHEMBL9235719 | 1.00 | PTPN1 (0.71) | PTPN1PTGS1PDE4ASNCAPDE3A | |
| SCHEMBL5567283 | 1.00 | PTPN1 (0.71) | PTPN1PTGS1PDE4ASNCAPDE3A | |
| SCHEMBL11562598 | 0.93 | PTPN1 (0.63) | PTPN1PTGS1PDE4ASNCAPDE3A | |
| SCHEMBL11562595 | 0.93 | PTPN1 (0.63) | PTPN1PTGS1PDE4ASNCAPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2518040-B1 | LOW-VISCOSITY LIQUID-CRYSTAL COMPOUND | FARNEX INCORPORATED (JP) | 2018-10-31 | — | — | EP | disclosed |
| US-20140194536-A1 | LOW-VISCOSITY LIQUID CRYSTAL COMPOUND | CHEMGENESIS INCORPORATED (JP) | 2014-07-10 | — | — | US | disclosed |
| US-8703922-B2 | Low-viscosity liquid crystal compound | CHEMGENESIS INCORPORATED (JP) | 2014-04-22 | — | — | US | disclosed |
| EP-2518040-A1 | LOW-VISCOSITY LIQUID-CRYSTAL COMPOUND | ChemGenesis Incorporated (JP) | 2012-10-31 | — | — | EP | disclosed |
| US-20120264923-A1 | LOW-VISCOSITY LIQUID CRYSTAL COMPOUND | CHEMGENESIS INCORPORATED (JP) | 2012-10-18 | — | — | US | disclosed |
| EP-0677520-B1 | Process for the preparation of alpha-tocopherol derivatives, and catalyst | EISAI CO LTD (JP) | 2000-08-30 | — | — | EP | disclosed |
| EP-0658552-B1 | Process for the preparation of alpha-tocopherol derivatives | EISAI CO LTD (JP) | 1999-03-31 | — | — | EP | disclosed |
| US-5610113-A | REACTION OF TRIMETHYLHYDROQUINONE AND ISOPHYTOL, CONDENSATION AND CYCLIZATION, SCANDIUM SAPONITE CATALYST | EISAI CO., LTD. (JP) | 1997-03-11 | — | — | US | disclosed |
| US-5536852-A | ETHERIFICATION, CYCLIZATION | EISAI CO., LTD. (JP) | 1996-07-16 | — | — | US | disclosed |
| US-5532387-A | CYCLIZATION OF TRIMETHYLHYDROQUINONE AND AN ALKENYL ALCOHOL, REUSABLE CATALYST, IIIB FLUOROSULFONATE, NITRATE, SULFATE, OR FLUOROALKYLSULFONATE | EISAI CO., LTD. (JP) | 1996-07-02 | — | — | US | disclosed |
| EP-0677520-A1 | Process for the preparation of alpha-tocopherol derivatives, and catalyst | Eisai Co., Ltd. (JP) | 1995-10-18 | — | — | EP | disclosed |
| EP-0658552-A1 | Process for the preparation of alpha-tocopherol derivatives | Eisai Co., Ltd. (JP) | 1995-06-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140194536-A1 | LOW-VISCOSITY LIQUID CRYSTAL COMPOUND | G6PD, GK, UGCG | PTPN1 1106/4885PTGS1 2252/4885PDE4A 466/4885 |
| US-20120264923-A1 | LOW-VISCOSITY LIQUID CRYSTAL COMPOUND | G6PD, GK, UGCG | PTPN1 1106/4885PTGS1 2252/4885PDE4A 466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.